New Technology for Diagnosing And Treating Male Impotence
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




New Technology for Diagnosing And Treating Male Impotence

FAIRFIELD, Conn., Nov. 26, 1996 -- Competitive Technologies, Inc. (AMEX: CTT) today announced the issuance of U.S. Patent No. 5,576,290 entitled "Compositions and Methods for the Diagnosis and Treatment of Psychogenic Erectile Dysfunction." CTT represents the University of Arizona as the exclusive licensing agent for this technology. The invention utilizes a peptide hormone analog designed by professors at the University of Arizona to diagnose and treat psychogenic erectile dysfunction in impotent men. It is estimated that there are over 100 million men worldwide who suffer from impotence.

CTT is currently working with the University of Arizona to locate a licensee with financial capability and technical resources to take the peptide through the regulatory process and into the marketplace.

The University of Arizona invention provides the only known patented method for the rapid and precise differentiation of physiological and psychological impotence. It is anticipated that this invention will allow the general practitioner to make an immediate differential diagnosis of a patient's problem, without referral to a specialist. The psychogenically impotent men responding to the drug can then be therapeutically treated. A recently concluded clinical study demonstrated increased effectiveness and safety over other known drug therapies for impotence. In addition, the drug does not require direct penile injection.

Dr. Mac Hadley, who is the inventor and a member of the Department of Anatomy at the University of Arizona, commented, "Presently most impotent men have no recourse other than to be treated by default -- though direct penile injection -- as if they have organic (physiological) erectile dysfunction. The present technology will be a salvation for the millions of men with psychogenic impotence."

Competitive Technologies, Inc. -- based in Fairfield, CT, with offices in Bethlehem, PA; Cleveland, OH; Osaka, Japan; And London, England -- is in the technology transfer business concentrating primarily on the commercialization and licensing of high-tech company and university research. Additional information about CTT can be found on its web-site: WWW.CTI.Lehigh.edu

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities